Navigation Links
Angioslide Announces the European Launch of New 300 mm Long Device Allowing Treatment of Entire Superficial Femoral Artery(SFA) with One Device
Date:9/8/2011

CAESAREA, Israel, September 8, 2011 /PRNewswire/ --

Angioslide Ltd. announces the first procedures with its new 5x300mm PROTEUS device for treating the Superficial Femoral Artery (SFA).  PROTEUS technology combines a Percutaneous Transluminal Angioplasty (PTA) balloon and embolic capture of particles in one device. The new 5x300 mm size joins Angioslide's current dedicated product line solutions for the lower limbs.

Initial treatments using the new PROTEUS device were conducted in leading world centers, Parkkrankenhaus Leipzig and Herzzentrum Bad Krozingen, located in Germany. The PROTEUS 5X300 mm makes it possible to treat lesions up to 300 mm with one device, while providing an immediate solution for embolic capture.

"Angioslide's breakthrough technology, now available also in 300 mm length as well, is a unique solution for lesions with high level of embolic material, including Chronic Total Occlusions (CTO), in stent-restenosis, thrombus containing lesions and post atherectomy PTA," said Prof. Thomas Zeller, Head of the Angiology Department, Heart Center Bad-Krozingen.

Prof.  Dierk Scheinert, Head of the Department of Angiology, Park-Krankenhaus Leipzig, adds, "We have been using the PROTEUS product line as part of our daily practice for a few years, and are working closely with the Angioslide team. I welcome the release of the 5X300 mm.  We can now use one device to treat patients with SFA diseases, which facilitates the procedural flow and makes the intervention cost-effective."

With the increase in life expectancy, diabetes prevalence, and number of high-risk patients, together  with the shift toward an "endovascular-first" approach as a preferred procedure over surgical revascularization, there is a growing need for expanding the current interventional "tool box" to accommodate procedures designed specifically to treat long and diffuse lesions in a quick and effective manner.

"We
'/>"/>

SOURCE Angioslide Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Angioslide Commercializes in the U.S. First Device to Combine Balloon Angioplasty and Embolic Capture
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)...  Men diagnosed with prostate cancer may struggle with ... sexual function. Often, many treatment conversations start with ... "Knowing what to expect is a large part of ... work very closely with men and their partners before, ... likely to occur," said Dr. David Samadi , ...
(Date:4/1/2015)... night, several months after a motorcycle crash paralyzed him from the ... Roosevelt "R.J." Anderson Jr. had a dream: he could walk again. ... friend using an exoskeleton device to walk at the Rehabilitation Institute ... receiving treatment. He decided then and there that he would one ... first person in Chicago to receive a ...
(Date:4/1/2015)... April 1, 2015  Diplomat Pharmacy, Inc. (NYSE: ... of BioRx, LLC, a highly specialized pharmacy and infusion ... and rare, chronic diseases based in Cincinnati, ... the combined resources and capabilities will make Diplomat one ... Diplomat and BioRx are dedicated to personalized medication therapies ...
Breaking Medicine Technology:Sex After Prostate Cancer Made Possible by World-Renowned Robotic Prostate Cancer Surgeon, Dr. David Samadi, using SMART Technique 2Sex After Prostate Cancer Made Possible by World-Renowned Robotic Prostate Cancer Surgeon, Dr. David Samadi, using SMART Technique 3Dream Comes True: Paralyzed Veteran Walks Again, Thanks to Robotic Exoskeleton System at Rehabilitation Institute of Chicago 2Dream Comes True: Paralyzed Veteran Walks Again, Thanks to Robotic Exoskeleton System at Rehabilitation Institute of Chicago 3Diplomat Completes Acquisition of BioRx 2Diplomat Completes Acquisition of BioRx 3Diplomat Completes Acquisition of BioRx 4
... Calif., Sept. 29 Zeltiq Aesthetics, a science-based medical device ... reduction of unwanted fat tissue, has announced the appointment of ... Nye succeeds Mitch Levinson, the founder of Zeltiq Aesthetics, who ... Officer and a member of the Board of Directors since ...
... N.Y., Sept. 29 Misonix, Inc. (Nasdaq: MSON ... technology, which in Europe is used for the ablation ... today announced plans to release fourth quarter and fiscal ... afternoon, October 1, 2009. Michael A. McManus, President ...
Cached Medicine Technology:Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern 2
(Date:4/2/2015)... Francisco, California (PRWEB) April 02, 2015 ... science campaign on March 19th, 2015, two years after ... the human microbiome. The biotech startup sparked the era ... engaged with the public to provide easily accessible information ... DNA sequencing technology. In less than two weeks from ...
(Date:4/2/2015)... Miami, FL (PRWEB) April 02, 2015 ... Track and Field gets its start! Runners have been ... are ready to start racing. Zensah®, a premium compression ... to help ensure the athletes are benefiting from ... , Zensah® is a Miami-based company, committed to using ...
(Date:4/2/2015)... On Wednesday, April 15, Registrar Corp will present ... where food industry professionals gather to network and assess ... Registrar Corp Vice President David Lennarz will go over ... food and beverages to the United States and inform ... inspection. The seminar will begin at 13:30 at Open ...
(Date:4/2/2015)... Grab your favorite latte or cup of tea ... trends with the all-new, half-hour debut of the lifestyle talk ... AM ET/PT, 6:00 AM CT, and 5:00 AM MT on ... product strategist Forbes Riley, Forbes Living TV brings ... entrepreneurs, inventors, and innovators whose creations are driving the latest ...
(Date:4/2/2015)... (PRWEB) April 02, 2015 Veale Outdoor ... now two digital billboards to its name, announces its ... in the Dixon/Sacramento area. Similar to the first ... in Rohnert Park, California, the addition means, in total, ... the much sought after tourist population traveling through the ...
Breaking Medicine News(10 mins):Health News:uBiome’s Dental Campaign to Give Portion of Proceeds to Charitable Dental Organization 2Health News:uBiome’s Dental Campaign to Give Portion of Proceeds to Charitable Dental Organization 3Health News:uBiome’s Dental Campaign to Give Portion of Proceeds to Charitable Dental Organization 4Health News:Zensah® Partners With Austin Track Club 2Health News:Zensah® Partners With Austin Track Club 3Health News:Registrar Corp to Present FDA Regulation Seminar at Worldfood Warsaw 2Health News:Registrar Corp to Present FDA Regulation Seminar at Worldfood Warsaw 3Health News:Forbes Living Showcases Trendsetters on Discovery Channel Transponder 2Health News:Forbes Living Showcases Trendsetters on Discovery Channel Transponder 3Health News:Veale Outdoor Advertising State of the Art Digital Billboards Reach 12 Million in SF Bay Area 2
... DURHAM, N.C. Wireless, personal computers used by cancer patients ... further cancer research, according to a study led by researchers ... see if patient-reported data generated at the point of care ... care and research," said Amy Abernethy, M.D., an oncologist at ...
... of individuals at risk for gastrointestinal cancers, researchers ... many people misjudge their actual degree of cancer ... support. Strategies for accurately assessing cancer risk are ... resources to prevent cancer in as many individuals ...
... for deadly cancer, , , THURSDAY, May 14 (HealthDay News) ... immune-based treatment boosted by 20 percent the overall survival ... , The findings are to be presented at the ... later this month in Florida. , The trial involved ...
... among breast cancer patients , , THURSDAY, May 14 (HealthDay ... ginger that many grandmothers are already familiar with, and ... undergoing chemotherapy. , "Ginger at a daily dose of ... nausea on the first day of chemotherapy, and reduced ...
... May 14 Thoratec Corporation (Nasdaq: THOR ), ... to save, support and restore failing hearts, said today ... JMP Securities Research Conference on Monday, May 18.David. V. ... provide an update on the company, beginning at 2 ...
... BIRMINGHAM, Ala., May 14 BioCryst Pharmaceuticals ... from a Phase 2 study of forodesine, the Company,s ... (CTCL). The data will be presented at the ... Oncology (ASCO) being held in Orlando, Florida from May ...
Cached Medicine News:Health News:Patient-centered approach to capturing data from cancer patients improves care and research 2Health News:Perceived cancer risks may not reflect actual risks or prevention needs 2Health News:Immune Therapy May Aid Kids With Neuroblastoma 2Health News:Ginger Eases Nausea From Chemo 2Health News:BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology 2Health News:BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology 3Health News:BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: